In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body weight reduction in adults without diabetes and Clinical trials of subcutaneous tirzepatide, retatrutide, and Download Scientific Diagram Novo Nordisk advances obesity candidate to late stage program after weight loss of less than 12% Seven Clinical Trials on Obesity Weight Loss Anticipated to Complete Soon Guideline Central PDF] Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomised, controlled, phase 1b trial. Semantic Scholar